Late-breaking science

The latest information on scientific trials.


Toni K. Choueiri, MD
Toni K. Choueiri, MD

The final results of a pivotal phase 3 trial of a polybacterial vaccine candidate for recurrent urinary tract infections (UTIs) in women was revealed during the Late Breaking Abstracts session “A Novel Sublingual Vaccine Will Dramatically Alter the Clinical Management of Recurrent Urinary Tract Infections in Women” at AUA2021.

Uromune, a sublingual spray developed and manufactured by Immunotek, has shown UTI-free rates of 33% to 78% at one year in early phase uncontrolled studies.

The late-breaker “Pembrolizumab vs. Placebo as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma (RCC): Randomized, Double-Blind, Phase 3 KEYNOTE-564 Study” reported improved disease-free survival and overall survival following nephrectomy for renal cell carcinoma for patients who were offered pembrolizumab versus placebo.

Adjuvant pembrolizumab reduced the risk for recurrence or death by 32% compared to placebo after a median follow-up of about 24 months.

Visit AUA2021 Daily News Online for more articles.